Author

Zachary W. Davis‐Gilbert

University of North Carolina at Chapel HillORCID 0000-0002-4070-0832Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Cancer Biology· 1 Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 4 Organism:human· 2 Assay:bulk RNA-seq· 1 Organism:mouse· 1 Assay:protein structure· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

David Harold DrewryiD· 2 shared Hans J. OhiD· 2 shared Mohammad Anwar HossainiD· 2 shared Abdiel Badillo-MartineziD· 1 shared Adam M. DrobishiD· 1 shared Alison Donnelly AxtmaniD· 1 shared Andrew J Armstrong· 1 shared Angeline E. Gavard· 1 shared

Activity by Year

2024-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

David Harold DrewryORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Development of NanoBRET cellular target engagement assays in primary neurons for activating mutants of p21-activated kinase 1

Jacob L. Capener, Abdiel Badillo-Martinez, Bassel Awada, Zachary W. Davis‐Gilbert, Thomas Krämer, Cameron S. Blair, Frances M. Bashore, Hassan Al‐Ali, Alison Donnelly Axtman

This paper develops NanoBRET assays for PAK1 and its mutant in primary neurons to evaluate inhibitor target engagement.

ACS Chemical Neuroscience · Oct 6, 2026Peer-reviewedPharmacology & Toxicology

Disruption of NUAK2-Mediated RNA Splicing by Trilaciclib Reveals a Therapeutic Vulnerability in AR-Indifferent Prostate Cancer

Umar Mehraj, Uran Maimekov, Shaista Manzoor, Emily Cordova, Manasiben Patel, Ikeer Y. Mancera-Ortiz, Stefanie Howell, Zachary W. Davis‐Gilbert, Mu‐En Wang, Ming Chen, Jung Wook Park, Yuzhuo Z. Wang, Jasmine Plummer, Andrew J Armstrong, Jiaoti Huang, , Everardo Macias

This paper identifies NUAK2 as a therapeutic target in AR-indifferent prostate cancer, showing trilaciclib inhibits NUAK2 and suppresses tumor growth.

bioRxiv · Nov 12, 2025 · PreprintCancer Biology

Identification of Direct-acting nsP2 Helicase Inhibitors with Anti-alphaviral Activity

M. Bose, John D. Sears, Kacey Marie Talbot, Yuan-Wei Norman Su, Scott Houliston, Mohammad Anwar Hossain, Zachary W. Davis‐Gilbert, Chunqing Zhao, Hans J. Oh, Peter J. Brown, Marcia K. Sanders, Stella R. Moorman, Durbadal Ojha, Jane Burdick, Isabella Law, , Timothy Mark Willson

This paper identifies and optimizes oxaspiropiperidine inhibitors targeting nsP2hel, showing nanomolar antiviral activity against multiple alphaviruses.

bioRxiv · Mar 4, 2025 · PreprintPharmacology & Toxicology

Structures of the human transcription factor brachyury offer insights into DNA recognition, and identify small molecule binders for the development of degraders for cancer therapy

Joseph A. Newman, Angeline E. Gavard, Nergis Imprachim, H. Aitkenhead, Hadley E. Sheppard, Paul Andrew Clarke, Mohammad Anwar Hossain, Louisa Temme, Hans J. Oh, Carrow I. Wells, Zachary W. Davis‐Gilbert, Paul Workman, O. Gileadi, David Harold Drewry

This study determines the structure of human brachyury, identifies DNA binding insights and a G177D variant, and discovers small molecule binders for potential cancer therapy.

bioRxiv · Jun 6, 2024 · PreprintMolecular Biology